GlassScriptPhysician profile
James Christopher Jordan
NPI 1811962574
$304.84
in general payments reported to CMS, 2019-2025
13 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $22.83 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $55.37 | 2025 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.00 | 2024-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $35.43 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $25.55 | 2025 | |
| Recordati_rare_diseases_inc. | $24.53 | 2025 | Panhematin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.51 | 2025 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $18.79 | 2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.60 | 2025 | |
| Lilly USA, LLC | $15.16 | 2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $15.16 | 2025 | Airsupra |
| Edwards Lifesciences Corporation | $14.04 | 2025 | |
| Radius Health, INC. | $13.91 | 2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $7.79 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.